Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosisRuben A. Mesa, Srđan Verstovšek, Vikas Gupta et al.|Leukemia|2022Cited by 63
Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK InhibitionNico Gagelmann, Nicolaus Kröger, Bárbara Mora et al.|Blood|2024Cited by 3